期刊
CURRENT OPINION IN IMMUNOLOGY
卷 39, 期 -, 页码 30-38出版社
CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2015.12.006
关键词
-
类别
资金
- Bristol Myers Squibb
- Roche
- Ventana
- Pfizer
- Celgene
Melanoma is at the forefront of development of systemic therapeutics with both molecular targeted therapies and immune checkpoint inhibitors as cornerstones of treatment. Although responses to molecularly targeted therapy is largely from blockade of oncogenic pathways, evidence is emerging of the immunomodulatory effects from BRAF inhibition. Additionally programmed-death-1 (PD-1) inhibitors have revolutionized the treatment of melanoma and are set to pave future improvements in other solid tumors. Combinations of PD-1 inhibitors with novel immune checkpoints or with molecularly targeted therapies are under investigation and may improve on the considerable progress made.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据